image header

News Releases

News Releases

Sep 17, 2020

ALX Oncology Added to Russell 2000® and 3000® Indexes Read more

Sep 8, 2020

ALX Oncology Announces Participation at Upcoming Investor Conferences Read more

Aug 27, 2020

ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights Read more

Jul 21, 2020

ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Read more

Jul 16, 2020

ALX Oncology Announces Pricing of Initial Public Offering Read more

Jun 12, 2020

ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Read more

May 29, 2020

ALX Oncology Presents Phase 1 Study Results of ALX148 in Combination with Standard Anti-Cancer Antibodies and Chemotherapy Regimens in Patients with Advanced Solid Tumors Read more

May 18, 2020

ALX Oncology to Present ALX148 Phase 1 Clinical Data at the Virtual 25th Congress of the European Hematology Association (EHA) Read more

May 14, 2020

ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Read more

May 4, 2020

ALX Oncology Announces Appointment of Rekha Hemrajani to Board of Directors Read more

Displaying 11 - 20 of 23